As the popularity of glucagon-like peptide-1 (GLP-1) receptor agonists—such as semaglutide and liraglutide—reaches an all-time high, the medical community is grappling with the systemic effects of these powerful medications. While these drugs have revolutionized the management of type 2 diabetes and obesity, their influence on surgical outcomes has remained a subject of intense scrutiny. A new, comprehensive study published in the April issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS), sheds critical light on how these medications influence recovery for patients undergoing abdominal body contouring.
The findings suggest a complex, nuanced reality: while GLP-1 medications do not appear to increase overall surgical risk, they may fundamentally alter the physiology of wound healing in ways that require closer clinical attention.
The Intersection of Pharmacotherapy and Plastic Surgery
Body contouring, specifically panniculectomy—a procedure designed to excise excess, hanging skin and adipose tissue from the lower abdomen—is a hallmark of post-bariatric care. As patients navigate massive weight loss, they are often left with significant skin laxity, which can lead to chronic skin infections, discomfort, and psychological distress.
In recent years, the profile of the "ideal" body contouring candidate has shifted. Plastic surgeons are increasingly treating patients who are utilizing GLP-1 receptor agonists (GLP1ra) to manage their weight or glycemic control. Because these medications are often used to optimize a patient’s health before elective surgery, the prevalence of GLP-1 use in surgical clinics has surged.
"As GLP-1 receptor agonist medications become increasingly integrated into the care of patients undergoing body contouring, our findings suggest that these drugs may have subtle effects on wound healing, even if they don’t increase overall surgical risks," explains lead author Dr. Zachary Andrew Koenig of the West Virginia University School of Medicine.
A Decade of Data: Study Methodology
To understand the long-term implications of these drugs, Dr. Koenig and his research team conducted a retrospective analysis spanning a full decade, from 2013 to 2023. By examining 373 patients who underwent non-bariatric abdominal panniculectomy at their institution, the researchers sought to isolate the specific impact of GLP-1 usage on post-operative recovery.
The study design was rigorous. To ensure the findings were not skewed by more invasive abdominal surgeries, the researchers explicitly excluded patients who were simultaneously undergoing bariatric surgery or hernia repair. This focus allowed the team to look specifically at the physiological response of the soft tissue to the surgical trauma of a panniculectomy in the context of ongoing GLP-1 therapy.
The data revealed a stark upward trend: approximately 21.7% of the cohort was actively using GLP-1 medications prior to their surgical intervention. Notably, this percentage increased significantly toward the end of the study period, reflecting the broader societal and clinical adoption of these drugs.
The Clinical Data: A Mixed Bag of Outcomes
When comparing the GLP-1 cohort to a control group of non-users, the researchers uncovered a fascinating, if paradoxical, set of clinical outcomes.
Increased Risk of Delayed Healing
The most concerning finding for surgeons was the rate of delayed wound healing. Patients utilizing GLP-1 agonists experienced a delayed healing rate of 18.5%, compared to just 7.5% in the control group. This discrepancy suggests that while the drugs are metabolically beneficial, they may interfere with the intricate biological cascade of tissue regeneration and collagen deposition required for the skin to knit back together post-incision.
A Surprising Benefit: Decreased Seroma Rates
Conversely, the data presented an unexpected benefit. GLP-1 users showed a significantly lower rate of seroma—the accumulation of fluid beneath the surgical site, which is a common and often frustrating complication in body contouring. In the GLP-1 group, the seroma rate was only 4.9%, compared to 14.0% among the non-users.
Stability in Other Metrics
For many other critical metrics, the two groups remained remarkably similar. There was no statistically significant difference in rates of wound dehiscence (the reopening of a surgical wound), post-operative infection, or the frequency of hospital readmissions. This suggests that the use of GLP-1 medications is not a "red light" for surgery, but rather a factor that necessitates a customized post-operative management strategy.
Patient Characteristics and Demographics
The study also highlighted the underlying health profiles of patients currently prescribed these medications. GLP-1 users in the cohort were statistically more likely to have comorbid conditions, including type 2 diabetes, chronic obstructive pulmonary disease (COPD), and hypertension.
Interestingly, despite the weight-loss-inducing properties of the medication, there was no significant difference in Body Mass Index (BMI) between the two groups at the time of surgery. This indicates that the surgeons were likely utilizing these medications to improve metabolic health markers rather than solely for weight reduction, or that the patients had reached a plateau in their weight loss trajectory by the time they reached the operating room.
Official Responses and Clinical Implications
The implications of this research are substantial for the field of plastic and reconstructive surgery. As practitioners, plastic surgeons are now forced to weigh the metabolic benefits of GLP-1 therapy against the potential for specific wound-healing complications.
The "Nuanced Interplay"
Dr. Koenig and his colleagues emphasize that the "complex and nuanced interplay" between these drugs and the body’s repair mechanisms is not yet fully understood. They hypothesize that GLP-1 agonists may affect soft tissue through unique, as-yet-unidentified physiological mechanisms. Because West Virginia has one of the highest rates of GLP-1 prescriptions in the United States, this study serves as a critical bellwether for the rest of the country.
The Call for Formal Guidelines
The study’s authors argue that while the surgery is broadly safe for this patient population, the findings underscore the need for "proactive management." Currently, there is a lack of consensus on whether patients should pause their GLP-1 medication prior to elective surgery. Some surgeons advocate for a "washout" period to mitigate risks, while others fear the metabolic rebound that might occur if the medication is discontinued.
The researchers conclude that there is an urgent need for the development of formal clinical guidelines. As the landscape of aesthetic and reconstructive medicine evolves, surgeons must rely on evidence-based protocols to navigate the intersection of systemic pharmacotherapy and local surgical outcomes.
Looking Ahead: The Future of Body Contouring Research
The study published in Plastic and Reconstructive Surgery is a vital first step, but it is not the final word. The researchers acknowledge the limitations of a single-center retrospective study and call for larger, multicenter prospective trials.
As the medical community continues to collect data, several questions remain:
- The "Washout" Effect: Does stopping GLP-1 medications two weeks before surgery change the wound-healing trajectory?
- Dose Dependency: Is there a threshold of dosage where the risk of delayed healing increases exponentially?
- Long-term Tissue Quality: Does long-term GLP-1 usage fundamentally alter the elasticity and quality of the skin, potentially affecting the long-term results of body contouring?
For now, surgeons are encouraged to treat each patient on an individual basis, carefully considering the patient’s overall metabolic health and their history of wound healing. The "rapidly evolving clinical landscape," as Dr. Koenig describes it, demands that practitioners remain vigilant, inquisitive, and committed to patient safety above all else.
As patient populations continue to change, the marriage of endocrinology and surgery will only become more common. Through ongoing research and transparent reporting of surgical outcomes, the medical community will eventually refine its approach, ensuring that the transformative benefits of body contouring remain accessible and safe for everyone, regardless of their pharmacological regimen.
For more information on the latest advancements in surgical outcomes and safety, visit the American Society of Plastic Surgeons or access the full study, "Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis," via the Plastic and Reconstructive Surgery journal portal.
About the Author
